Skip to main content

Advertisement

SpringerLink
Log in

Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia—sub-chronic and early postnatal PCP treatment in attentional set-shifting

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

Rationale

Therapies treating cognitive impairments in schizophrenia especially deficits in executive functioning are not available at present.

Objective

The current study evaluated the effect of ampakine CX516 in reversing deficits in executive functioning as represented in two animal models of schizophrenia and assessed by a rodent analog of the intradimensional–extradimensional (ID–ED) attentional set-shifting task. The second generation antipsychotic, sertindole, provided further validation of the schizophrenia-like disease models.

Methods

Animals were subjected to (a) sub-chronic or (b) early postnatal phencyclidine (PCP) treatment regimes: (a) Administration of either saline or PCP (5 mg/kg, intraperitonally b.i.d. for 7 days) followed by a 7-day washout period and testing on day 8. (b) On postnatal days (PNDs) 7, 9, and 11, rats were subjected to administration of either saline or PCP (20 mg/kg, subcutaneously (s.c.)) and tested on PNDs 56–95, after reaching adulthood. The single test session required rats to dig for food rewards in a series of discriminations following acute administration of either vehicle, or CX516 (5–40 mg/kg, s.c.), or sertindole (1.25 mg/kg, perorally).

Results

The specific extradimensional deficits produced by sub-chronic or early postnatal PCP treatment were significantly attenuated by sertindole and dose-dependently by CX516.

Conclusion

Findings here further establish PCP treatment as model of executive functioning deficits related to schizophrenia and provide evidence that direct glutamatergic interventions could improve these, when assessed in the ID–ED attentional set-shifting task.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  • Arai AC, Kessler M (2007) Pharmacology of ampakine modulators: from AMPA receptors to synapses and behavior. Curr Drug Targets 8:583–602

    Article  PubMed  CAS  Google Scholar 

  • Arai A, Kessler M, Xiao P, Ambros-Ingerson J, Rogers G, Lynch G (1994) A centrally active drug that modulates AMPA receptor gated currents. Brain Res 638:343–346

    Article  PubMed  CAS  Google Scholar 

  • Barense MD, Fox MT, Baxter MG (2002) Aged rats are impaired on an attentional set-shifting task sensitive to medial frontal cortex damage in young rats. Learn Mem 9:191–201

    Article  PubMed  Google Scholar 

  • Baumbarger PJ, Muhlhauser M, Zhai J, Yang CR, Nisenbaum ES (2001) Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors in prefrontal cortical pyramidal neurons by a novel allosteric potentiator. J Pharmacol Exp Ther 298:86–102

    PubMed  CAS  Google Scholar 

  • Bayer SA, Altman J, Russo RJ, Zhang X (1993) Timetables of neurogenesis in the human brain based on experimentally determined patterns in the rat. Neurotoxicology 14:83–144

    PubMed  CAS  Google Scholar 

  • Birrell JM, Brown VJ (2000) Medial frontal cortex mediates perceptual attentional set shifting in the rat. J Neurosci 20:4320–4324

    PubMed  CAS  Google Scholar 

  • Black MD (2005) Therapeutic potential of positive AMPA modulators and their relationship to AMPA receptor subunits. A review of preclinical data. Psychopharmacology (Berl) 179:154–163

    Article  CAS  Google Scholar 

  • Black MD, Wotanis J, Schilp DE, Hanak SE, Sorensen SM, Wettstein JG (2000) Effect of AMPA receptor modulators on hippocampal and cortical function. Eur J Pharmacol 394:85–90

    Article  PubMed  CAS  Google Scholar 

  • Broberg BV, Dias R, Glenthoj BY, Olsen CK (2008) Evaluation of a neurodevelopmental model of schizophrenia—early postnatal PCP treatment in attentional set-shifting. Behav Brain Res 190:160–163

    Article  PubMed  CAS  Google Scholar 

  • Carlsson A, Waters N, Waters S, Carlsson ML (2000) Network interactions in schizophrenia—therapeutic implications. Brain Res Brain Res Rev 31:342–349

    Article  PubMed  CAS  Google Scholar 

  • Clancy B, Darlington RB, Finlay BL (2001) Translating developmental time across mammalian species. Neuroscience 105:7–17

    Article  PubMed  CAS  Google Scholar 

  • Cochran SM, Kennedy M, McKerchar CE, Steward LJ, Pratt JA, Morris BJ (2003) Induction of metabolic hypofunction and neurochemical deficits after chronic intermittent exposure to phencyclidine: differential modulation by antipsychotic drugs. Neuropsychopharmacology 28:265–275

    Article  PubMed  CAS  Google Scholar 

  • Deutsch SI, Mastropaolo J, Rosse RB (1998) Neurodevelopmental consequences of early exposure to phencyclidine and related drugs. Clin Neuropharmacol 21:320–332

    PubMed  CAS  Google Scholar 

  • Dias R, Robbins TW, Roberts AC (1996a) Primate analogue of the Wisconsin Card Sorting Test: effects of excitotoxic lesions of the prefrontal cortex in the marmoset. Behav Neurosci 110:872–886

    Article  PubMed  CAS  Google Scholar 

  • Dias R, Robbins TW, Roberts AC (1996b) Dissociation in prefrontal cortex of affective and attentional shifts. Nature 380:69–72

    Article  PubMed  CAS  Google Scholar 

  • du Bois TM, Huang XF (2007) Early brain development disruption from NMDA receptor hypofunction: relevance to schizophrenia. Brain Res Rev 53:260–270

    Article  PubMed  Google Scholar 

  • Egerton A, Reid L, McKerchar CE, Morris BJ, Pratt JA (2005) Impairment in perceptual attentional set-shifting following PCP administration: a rodent model of set-shifting deficits in schizophrenia. Psychopharmacology (Berl ) 179:77–84

    Article  CAS  Google Scholar 

  • Fagerlund B, Mackeprang T, Gade A, Glenthoj BY (2004) Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr 9:364–374

    PubMed  Google Scholar 

  • Featherstone RE, Rizos Z, Nobrega JN, Kapur S, Fletcher PJ (2007) Gestational methylazoxymethanol acetate treatment impairs select cognitive functions: parallels to schizophrenia. Neuropsychopharmacology 32:483–492

    Article  PubMed  CAS  Google Scholar 

  • Gallhofer B, Jaanson P, Mittoux A, Tanghoj P, Lis S, Krieger S (2007) Course of recovery of cognitive impairment in patients with schizophrenia: a randomised double-blind study comparing sertindole and haloperidol. Pharmacopsychiatry 40:275–286

    Article  PubMed  CAS  Google Scholar 

  • Goetghebeur P, Dias R (2009) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rat—a back translational study. Psychopharmacology (Berl) 202:287–293

    Article  CAS  Google Scholar 

  • Goff DC, Coyle JT (2001) The emerging role of glutamate in the pathophysiology and treatment of schizophrenia. Am J Psychiatry 158:1367–1377

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, Leahy L, Berman I, Posever T, Herz L, Leon AC et al (2001) A placebo-controlled pilot study of the ampakine CX516 added to clozapine in schizophrenia. J Clin Psychopharmacol 21:484–487

    Article  PubMed  CAS  Google Scholar 

  • Goff DC, Lamberti JS, Leon AC, Green MF, Miller AL, Patel J et al (2008) A placebo-controlled add-on trial of the ampakine, CX516, for cognitive deficits in schizophrenia. Neuropsychopharmacology 33:465–472

    Article  PubMed  CAS  Google Scholar 

  • Granger R, Staubli U, Davis M, Perez Y, Nilsson L, Rogers GA et al (1993) A drug that facilitates glutamatergic transmission reduces exploratory activity and improves performance in a learning-dependent task. Synapse 15:326–329

    Article  PubMed  CAS  Google Scholar 

  • Green MF (1996) What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 153:321–330

    PubMed  CAS  Google Scholar 

  • Green MF, Bracha HS, Satz P, Christenson CD (1994) Preliminary evidence for an association between minor physical anomalies and second trimester neurodevelopment in schizophrenia. Psychiatry Res 53:119–127

    Article  PubMed  CAS  Google Scholar 

  • Hampson RE, Rogers G, Lynch G, Deadwyler SA (1998a) Facilitative effects of the ampakine CX516 on short-term memory in rats: correlations with hippocampal neuronal activity. J Neurosci 18:2748–2763

    PubMed  CAS  Google Scholar 

  • Hampson RE, Rogers G, Lynch G, Deadwyler SA (1998b) Facilitative effects of the ampakine CX516 on short-term memory in rats: enhancement of delayed-nonmatch-to-sample performance. J Neurosci 18:2740–2747

    PubMed  CAS  Google Scholar 

  • Hyman SE, Fenton WS (2003) Medicine. What are the right targets for psychopharmacology? Science 299:350–351

    Article  PubMed  CAS  Google Scholar 

  • Ikonomidou C, Bosch F, Miksa M, Bittigau P, Vockler J, Dikranian K et al (1999) Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283:70–74

    Article  PubMed  CAS  Google Scholar 

  • Ingvar M, Ambros-Ingerson J, Davis M, Granger R, Kessler M, Rogers GA et al (1997) Enhancement by an ampakine of memory encoding in humans. Exp Neurol 146:553–559

    Article  PubMed  CAS  Google Scholar 

  • Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301–1308

    PubMed  CAS  Google Scholar 

  • Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20:201–225

    Article  PubMed  CAS  Google Scholar 

  • Jentsch JD, Tran A, Le D, Youngren KD, Roth RH (1997) Subchronic phencyclidine administration reduces mesoprefrontal dopamine utilization and impairs prefrontal cortical-dependent cognition in the rat. Neuropsychopharmacology 17:92–99

    Article  PubMed  CAS  Google Scholar 

  • Jones P, Rodgers B, Murray R, Marmot M (1994) Child development risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344:1398–1402

    Article  PubMed  CAS  Google Scholar 

  • Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51:199–214

    PubMed  CAS  Google Scholar 

  • Larson J, Lieu T, Petchpradub V, LeDuc B, Ngo H, Rogers GA et al (1995) Facilitation of olfactory learning by a modulator of AMPA receptors. J Neurosci 15:8023–8030

    PubMed  CAS  Google Scholar 

  • Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug: sernyl. AMA Arch Neurol Psychiatry 81:363–369

    PubMed  CAS  Google Scholar 

  • Lynch G (2006) Glutamate-based therapeutic approaches: ampakines. Curr Opin Pharmacol 6:82–88

    Article  PubMed  CAS  Google Scholar 

  • Lynch G, Granger R, Ambros-Ingerson J, Davis CM, Kessler M, Schehr R (1997) Evidence that a positive modulator of AMPA-type glutamate receptors improves delayed recall in aged humans. Exp Neurol 145:89–92

    Article  PubMed  CAS  Google Scholar 

  • Marenco S, Egan MF, Goldberg TE, Knable MB, McClure RK, Winterer G et al (2002) Preliminary experience with an ampakine (CX516) as a single agent for the treatment of schizophrenia: a case series. Schizophr Res 57:221–226

    Article  PubMed  Google Scholar 

  • Matsui M, Sumiyoshi T, Arai H, Higuchi Y, Kurachi M (2008) Cognitive functioning related to quality of life in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 32:280–287

    Article  PubMed  Google Scholar 

  • McLean SL, Beck JP, Woolley ML, Neill JC (2008) A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res 189:152–158

    Article  PubMed  CAS  Google Scholar 

  • Morris BJ, Cochran SM, Pratt JA (2005) PCP: from pharmacology to modelling schizophrenia. Curr Opin Pharmacol 5:101–106

    Article  PubMed  CAS  Google Scholar 

  • Owen AM, Roberts AC, Polkey CE, Sahakian BJ, Robbins TW (1991) Extra-dimensional versus intra-dimensional set shifting performance following frontal lobe excisions, temporal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 29:993–1006

    Article  PubMed  CAS  Google Scholar 

  • Pantelis C, Barber FZ, Barnes TR, Nelson HE, Owen AM, Robbins TW (1999) Comparison of set-shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res 37:251–270

    Article  PubMed  CAS  Google Scholar 

  • Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV et al (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102–1107

    Article  PubMed  CAS  Google Scholar 

  • Pignatelli D, Xiao F, Gouveia AM, Ferreira JG, Vinson GP (2006) Adrenarche in the rat. J Endocrinol 191:301–308

    Article  PubMed  CAS  Google Scholar 

  • Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J NeuroSci 21:1070–1076

    Article  PubMed  Google Scholar 

  • Rodefer JS, Nguyen TN, Karlsson JJ, Arnt J (2008) Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by sertindole and a 5-HT(6) receptor antagonist: comparison among antipsychotics. Neuropsychopharmacology 33:2657–2666

    Article  PubMed  CAS  Google Scholar 

  • Rogan MT, Staubli UV, LeDoux JE (1997) AMPA receptor facilitation accelerates fear learning without altering the level of conditioned fear acquired. J Neurosci 17:5928–5935

    PubMed  CAS  Google Scholar 

  • Staubli U, Perez Y, Xu FB, Rogers G, Ingvar M, Stone-Elander S et al (1994) Centrally active modulators of glutamate receptors facilitate the induction of long-term potentiation in vivo. Proc Natl Acad Sci U S A 91:11158–11162

    Article  PubMed  CAS  Google Scholar 

  • Wang CZ, Johnson KM (2005) Differential effects of acute and subchronic administration on phencyclidine-induced neurodegeneration in the perinatal rat. J Neurosci Res 81:284–292

    Article  PubMed  CAS  Google Scholar 

  • Wang C, McInnis J, Ross-Sanchez M, Shinnick-Gallagher P, Wiley JL, Johnson KM (2001) Long-term behavioral and neurodegenerative effects of perinatal phencyclidine administration: implications for schizophrenia. Neuroscience 107:535–550

    Article  PubMed  CAS  Google Scholar 

  • Weinberger DR (2007) Schizophrenia drug says goodbye to dopamine. Nat Med 13:1018–1019

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

Funding from H. Lundbeck A/S, the Faculty of Health Sciences, University of Copenhagen, and the Graduate School of In Vivo Pharmacology, University of Copenhagen supported this research. The authors specifically thank Mr. Pascal Goetghebeur, Mrs. Tanja Bruun, and Mr. Christian S. Pedersen for help and training in the attentional set-shifting task procedure. Additionally, Mr. Anders Sylvest is thanked for his help in preparing the animals for the final test.

Ethical standards

All animal procedures were carried out in compliance with the European Commission Directive 86/609/EEC and with Danish law regulating experiments on animals.

Author information

Authors and Affiliations

  1. Department of In Vivo Neurobiology, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark

    Brian Villumsen Broberg & Christina Kurre Olsen

  2. Department of Discovery ADME, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark

    Dorrit Bjerg Larsen

  3. Department of Psychopharmacology, H. Lundbeck A/S, Ottiliavej 9, 2500, Valby, Denmark

    Rebecca Dias

  4. Center for Neuropsychiatric Schizophrenia Research, Faculty of Health Sciences, Psychiatric Center Glostrup, University of Copenhagen, Glostrup, Denmark

    Brian Villumsen Broberg & Birte Yding Glenthøj

Authors
  1. Brian Villumsen Broberg
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Birte Yding Glenthøj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Rebecca Dias
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dorrit Bjerg Larsen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Christina Kurre Olsen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian Villumsen Broberg.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Broberg, B.V., Glenthøj, B.Y., Dias, R. et al. Reversal of cognitive deficits by an ampakine (CX516) and sertindole in two animal models of schizophrenia—sub-chronic and early postnatal PCP treatment in attentional set-shifting. Psychopharmacology 206, 631–640 (2009). https://doi.org/10.1007/s00213-009-1540-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00213-009-1540-5

Keywords

Search

Navigation